Event-free survival.

Event-free survival defined as the time from the beginning of first-line treatment to a first adverse event: death, progression requiring a change in therapy, infections or thrombocytopenic hemorrhage requiring hospitalization, and autoimmune hemolytic anemia for the patients who responded to the first-line treatment with 2-CdA+P (continuous line) and Chl+P (dotted line).